Breast Imaging

Should You Order Axillary Ultrasound for Small, Clinically Node-Negative Breast Cancer?

·
Should You Order Axillary Ultrasound for Small, Clinically Node-Negative Breast Cancer?

A 54-year-old woman presents for surgical consultation following a recent stereotactic biopsy that confirmed a 1.4 cm, grade 2 invasive ductal carcinoma in her left breast. Her clinical breast exam is unremarkable, with no palpable masses or axillary adenopathy. As the multidisciplinary team plans for a lumpectomy and sentinel lymph node biopsy, the immediate question arises: is preoperative imaging of the axilla necessary? This patient’s low-risk features—a small primary tumor and a clinically negative axilla—place her into a specific clinical workflow where the value of dedicated axillary imaging must be carefully considered. This article details the American College of Radiology (ACR) guidance for this exact scenario, explaining why axillary ultrasound is rated as `May be appropriate` and how to integrate its findings into the patient’s care plan.

Who Fits This Clinical Scenario for Axillary Staging?

This guidance applies to a well-defined patient population: females with a newly diagnosed breast cancer where the primary tumor is 2 cm or less in its greatest dimension (T1 stage) and who are clinically node-negative. “Clinically node-negative” means that a thorough physical examination by an experienced clinician reveals no palpable, firm, or fixed lymph nodes in the axilla.

It is crucial to distinguish this scenario from similar but distinct clinical presentations that follow different diagnostic pathways:

  • Clinically Node-Positive Patients: If the patient has palpable or suspicious axillary lymph nodes on exam, regardless of tumor size, they fit a different scenario. Preoperative imaging and biopsy are essential in these cases to confirm nodal disease.
  • Larger Primary Tumors: For breast cancers greater than 2 cm, the pre-test probability of axillary metastasis is higher, which can strengthen the indication for preoperative axillary imaging.
  • Neoadjuvant Chemotherapy Candidates: Patients slated for systemic therapy before surgery (neoadjuvant chemotherapy), such as those with triple-negative or HER2-positive cancers, require baseline axillary staging to assess treatment response. Their imaging pathway is more intensive.
  • Presenting with a Palpable Axillary Lump: If the patient’s initial symptom is a new lump in the axilla, the workup is different and focuses on characterizing the lump itself, which may or may not be related to an occult breast primary.

This article is exclusively for the initial workup of the axilla in the T1, clinically node-negative patient after diagnostic breast imaging has been completed.

What Diagnoses Are You Working Up in This Scenario?

The primary goal of imaging the axilla in this context is to detect occult nodal metastases that were not apparent on physical exam. Identifying metastatic disease preoperatively can significantly alter surgical and systemic therapy planning. The differential considerations for findings on axillary imaging include:

Axillary Lymph Node Metastases
This is the most consequential diagnosis. Even in small, clinically node-negative tumors, a meaningful minority of patients will have occult metastases. Identifying a positive node via imaging and subsequent biopsy allows for accurate staging (upstaging the patient from clinical N0 to pathologic N1) before the primary surgery. This information can guide the decision between a sentinel lymph node biopsy (SLNB) and a more extensive axillary lymph node dissection (ALND) or targeted axillary dissection (TAD).

Benign Reactive Adenopathy
Lymph nodes can become enlarged and prominent for reasons other than cancer, including inflammation from the tumor itself, post-biopsy changes, or unrelated systemic inflammatory or infectious conditions. Ultrasound is highly effective at evaluating nodal morphology—such as the preservation of the fatty hilum and the thickness and uniformity of the cortex—to help distinguish benign reactive changes from malignant infiltration.

Normal Lymph Nodes
Confirming the presence of normal-appearing lymph nodes is a common and reassuring outcome. This finding supports the plan to proceed with SLNB as the standard-of-care surgical staging procedure, reinforcing the initial clinical assessment.

Why Is Axillary Ultrasound Rated ‘May Be Appropriate’ for Small, Node-Negative Cancers?

For a female patient with a newly diagnosed breast cancer of 2 cm or less and a clinically negative axilla, the ACR Appropriateness Criteria rate US axilla as `May be appropriate`. This rating reflects a nuanced clinical situation: while not mandatory for every patient, the study provides valuable information in a non-invasive manner and can alter management in a significant subset of cases.

The rationale for this recommendation is based on a balance of diagnostic yield, risk, and impact on care. Axillary ultrasound is a zero-radiation (0 mSv) and contrast-free examination that offers high-resolution imaging of the nodal basin. Its primary strength is the detailed assessment of lymph node morphology. Features suspicious for malignancy include cortical thickening (often asymmetric or focal), a rounded shape (loss of the normal reniform or bean shape), and effacement or complete loss of the central fatty hilum. If a suspicious node is identified, ultrasound provides real-time guidance for a fine-needle aspiration (FNA) or core needle biopsy, allowing for a definitive pathologic diagnosis before surgery.

The “May be appropriate” designation, rather than “Usually appropriate,” acknowledges that the incidence of positive nodes in this low-risk population is relatively low, and many institutions may elect to proceed directly to surgical staging with SLNB without preoperative imaging. However, identifying the patients who do have nodal disease preoperatively avoids a potential second surgery (a completion ALND if the sentinel node is unexpectedly positive) and allows for more comprehensive treatment planning from the outset.

Alternative, more advanced imaging modalities are considered `Usually not appropriate` for this specific, limited indication:

  • MRI breast without and with IV contrast: While breast MRI is excellent for evaluating the extent of disease within the breast, it is less specific for axillary nodal assessment than a dedicated ultrasound. It adds significant cost and scan time without a clear benefit for axillary staging in this low-risk group.
  • FDG-PET/CT skull base to mid-thigh: This is a powerful tool for detecting systemic and distant metastatic disease. However, for a small, clinically node-negative breast cancer, the risk of distant metastases is very low. Ordering a PET/CT for initial axillary staging would expose the patient to significant radiation (☢☢☢☢ 10-30 mSv) and is not cost-effective or clinically justified.

What Is the Downstream Workflow After an Axillary Ultrasound?

The results of the axillary ultrasound create clear, branching pathways for patient management. The goal is to ensure the correct surgical and, if necessary, systemic treatment is planned.

If the Ultrasound is Negative
If the ultrasound shows only normal-appearing or benign-appearing lymph nodes, the patient’s staging remains clinically node-negative. The standard-of-care next step is to proceed with the planned sentinel lymph node biopsy (SLNB) at the time of the breast surgery. A negative ultrasound does not eliminate the need for SLNB, as it cannot reliably detect micrometastatic disease.

If the Ultrasound is Positive (Suspicious Node Identified)
When one or more lymph nodes display suspicious morphologic features, the immediate next step is an ultrasound-guided needle biopsy (FNA or core biopsy) of the most abnormal node.

  • If the biopsy confirms metastasis: The patient is now considered pathologically node-positive (pN1). This is a critical change in their stage and management. The multidisciplinary team may now recommend neoadjuvant chemotherapy before surgery. The surgical plan for the axilla will also change, potentially from SLNB to an axillary lymph node dissection (ALND) or a targeted axillary dissection (TAD), where the biopsy-proven positive node is marked with a clip for specific removal along with the sentinel nodes.
  • If the biopsy is negative for metastasis: Despite the suspicious imaging appearance, a negative biopsy result means the patient is still treated as clinically node-negative. However, the false-negative rate of FNA/core biopsy is not zero. Therefore, the patient still proceeds to SLNB. The surgeon and radiologist should communicate about the location of the previously biopsied node, as it may warrant special attention during surgery.

Common Pitfalls in Axillary Staging for Early Breast Cancer

Navigating the workup for T1, clinically node-negative breast cancer requires attention to detail to avoid common errors that can impact staging accuracy and treatment.

  • Pitfall: Incomplete Sonographic Evaluation. A thorough axillary ultrasound must include evaluation of all three nodal levels, particularly levels I and II, where most metastases occur. The sonographer should scan systematically from the latissimus dorsi muscle posteriorly to the pectoralis muscle anteriorly.
  • Pitfall: Over-relying on Nodal Size. Malignant nodes are not always large, and large nodes are not always malignant. Morphologic criteria—such as cortical thickness, shape, and loss of the fatty hilum—are far more reliable indicators of metastasis than size alone.
  • Pitfall: Ignoring Vaccination History. Recent vaccinations (especially for COVID-19 or influenza) in the ipsilateral arm can cause significant reactive adenopathy that can perfectly mimic malignancy on ultrasound. Always obtain this history before recommending a biopsy for suspicious-appearing nodes.

If an axillary node is highly suspicious on imaging but a needle biopsy is negative or yields insufficient material, escalation via a multidisciplinary discussion is warranted to decide between a repeat biopsy or proceeding directly to surgical evaluation.

Related ACR Topics and Tools

For further reading on adjacent clinical scenarios and to explore the tools used in developing these recommendations, the following resources are available. These tools help ensure that imaging decisions are evidence-based, safe, and appropriate for each unique patient presentation.

Frequently Asked Questions

Why isn’t axillary ultrasound ‘Usually Appropriate’ for all small, node-negative breast cancers?

The ‘May be appropriate’ rating reflects that for this specific low-risk group (tumor ≤ 2 cm, clinically negative nodes), the overall incidence of occult nodal disease is relatively low. While ultrasound can identify these cases and alter management, some clinical pathways reasonably proceed directly to sentinel lymph node biopsy (SLNB) without preoperative imaging. The choice often depends on institutional protocols and multidisciplinary team consensus.

If the axillary ultrasound is negative, is sentinel lymph node biopsy still necessary?

Yes, absolutely. Axillary ultrasound is not sensitive enough to detect microscopic deposits of cancer cells (micrometastases). A negative ultrasound provides reassurance but does not replace surgical staging. SLNB remains the gold standard for accurately staging the axilla in clinically node-negative patients.

Does the histology of the breast cancer, like invasive lobular versus ductal, affect the decision to order an axillary US?

While some data suggest different patterns of metastasis for lobular carcinoma, the current ACR guidelines for this specific scenario (T1 tumor, clinically node-negative) do not formally stratify the recommendation based on histology. However, a clinician might have a lower threshold to order the ultrasound for tumors with other high-risk features, such as high grade or lymphovascular invasion on the initial biopsy.

What should be done if a patient had a recent vaccination in the same arm as their breast cancer?

This is a critical piece of clinical history. Recent vaccinations can cause prominent reactive axillary lymphadenopathy that can appear suspicious on ultrasound. The radiologist must be informed of the date and side of vaccination. If nodes have a reactive appearance and the history fits, the best course may be a short-term follow-up ultrasound in a few weeks rather than an immediate biopsy, to allow the reactive changes to resolve.

Is MRI a good alternative if the axillary ultrasound is equivocal?

No. For the specific purpose of initial axillary staging in this low-risk population, breast MRI is rated as ‘Usually not appropriate’ by the ACR. If an ultrasound finding is equivocal or suspicious, the recommended next step is not another imaging test but rather a tissue diagnosis via ultrasound-guided biopsy or proceeding to surgical evaluation with SLNB.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026